(MOH) Molina Healthcare - Overview
Sector: Healthcare | Industry: Healthcare Plans | Exchange: NYSE (USA) | Market Cap: 7.372m USD | Total Return: -57.4% in 12m
Medicaid Plans, Medicare Plans, Marketplace Plans, Managed Care
Total Rating 29
Safety 81
Buy Signal -0.34
Healthcare Plans
Industry Rotation: +3.9
Industry Rotation: +3.9
Market Cap:
7.37B
Avg Turnover: 170M USD
Avg Turnover: 170M USD
ATR:
4.70%
Peers RS (IBD): 10.7
Peers RS (IBD): 10.7
Risk 5d forecast
Volatility62.4%
Rel. Tail Risk-12.7%
Reward TTM
Sharpe Ratio-1.21
Alpha-62.91
Character TTM
Beta0.081
Beta Downside-0.522
Drawdowns 3y
Max DD70.76%
CAGR/Max DD-0.30
EPS (Earnings per Share)
EPS CAGR: -52.38%
EPS Trend: -44.1%
EPS Trend: -44.1%
Last SUE: -4.00
Qual. Beats: 0
Qual. Beats: 0
Revenue
Rev. CAGR: 10.70%
Rev. Trend: 97.7%
Rev. Trend: 97.7%
Last SUE: 2.55
Qual. Beats: 6
Qual. Beats: 6
Warnings
Choppy
Tailwinds
No distinct edge detected
Description: MOH Molina Healthcare
Molina Healthcare, Inc. (MOH) is a U.S.-based managed-care provider focused on low-income populations, delivering Medicaid, Medicare, and Marketplace health plans across the country. Founded in 1980 and headquartered in Long Beach, California, the firm operates through four segments: Medicaid, Medicare, Marketplace, and Other.
As of Q4 2025, Molina reported a 7% year-over-year revenue increase to $2.31 billion, driven by a 5% rise in Medicaid enrollment (now serving roughly 4.2 million members) and strong growth in its Medicare Advantage business, which added 200,000 new members in the quarter. The company’s operating margin expanded to 3.8%, reflecting cost-control initiatives and higher reimbursement rates from recent federal Medicaid expansions. Sector-wide, rising healthcare inflation and continued policy support for public-payor programs remain key catalysts for Molina’s growth.
For a deeper dive, consider reviewing ValueRay’s detailed analysis of MOH.
- Medicaid enrollment growth boosts premium revenue
- Medicare Advantage plan expansion drives membership gains
- State-level contract renewals impact revenue stability
- Healthcare utilization trends affect medical care costs
- Government funding changes pose regulatory risk
Piotroski VR‑10 (Strict)
4.5
| Net Income: 472.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.04 > 0.02 and ΔFCF/TA -7.57 > 1.0 |
| NWC/Revenue: 11.17% < 20% (prev 12.00%; Δ -0.83% < -1%) |
| CFO/TA -0.03 > 3% & CFO -535.0m > Net Income 472.0m |
| Net Debt (-298.0m) to EBITDA (976.0m): -0.31 < 3 |
| Current Ratio: 1.69 > 1.5 & < 3 |
| Outstanding Shares: last quarter (50.8m) vs 12m ago -11.97% < -2% |
| Gross Margin: 8.97% > 18% (prev 0.12%; Δ 885.4% > 0.5%) |
| Asset Turnover: 291.2% > 50% (prev 260.1%; Δ 31.17% > 0%) |
| Interest Coverage Ratio: 4.07 > 6 (EBITDA TTM 976.0m / Interest Expense TTM 192.0m) |
Altman Z''
3.56
| A: 0.33 (Total Current Assets 12.44b - Total Current Liabilities 7.37b) / Total Assets 15.56b |
| B: 0.23 (Retained Earnings 3.60b / Total Assets 15.56b) |
| C: 0.05 (EBIT TTM 781.0m / Avg Total Assets 15.60b) |
| D: 0.31 (Book Value of Equity 3.62b / Total Liabilities 11.49b) |
| Altman-Z'' Score: 3.56 = A |
Beneish M
-2.58
| DSRI: 0.96 (Receivables 3.53b/3.30b, Revenue 45.43b/40.65b) |
| GMI: 1.30 (GM 8.97% / 11.65%) |
| AQI: 1.10 (AQ_t 0.18 / AQ_t-1 0.16) |
| SGI: 1.12 (Revenue 45.43b / 40.65b) |
| TATA: 0.06 (NI 472.0m - CFO -535.0m) / TA 15.56b) |
| Beneish M-Score: -2.58 (Cap -4..+1) = A |
What is the price of MOH shares?
As of April 11, 2026, the stock is trading at USD 145.88 with a total of 598,734 shares traded.
Over the past week, the price has changed by +1.76%, over one month by +3.23%, over three months by -19.77% and over the past year by -57.43%.
Over the past week, the price has changed by +1.76%, over one month by +3.23%, over three months by -19.77% and over the past year by -57.43%.
Is MOH a buy, sell or hold?
Molina Healthcare has received a consensus analysts rating of 3.75.
Therefor, it is recommend to hold MOH.
- StrongBuy: 6
- Buy: 1
- Hold: 8
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the MOH price?
| Analysts Target Price | 151.1 | 3.6% |
Molina Healthcare (MOH) - Fundamental Data Overview
as of 09 April 2026
P/E Trailing = 15.8666 P/E Forward = 27.6243
P/S = 0.1692
P/B = 1.7843
P/EG = 1.3827
Revenue TTM = 45.43b USD
EBIT TTM = 781.0m USD
EBITDA TTM = 976.0m USD
Long Term Debt = 3.77b USD (from longTermDebt, last quarter)
Short Term Debt = unknown (none)
Debt = 3.95b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -298.0m USD (from netDebt column, last quarter)
Enterprise Value = 7.07b USD (7.37b + Debt 3.95b - CCE 4.25b)
Interest Coverage Ratio = 4.07 (Ebit TTM 781.0m / Interest Expense TTM 192.0m)
EV/FCF = -11.12x (Enterprise Value 7.07b / FCF TTM -636.0m)
FCF Yield = -8.99% (FCF TTM -636.0m / Enterprise Value 7.07b)
FCF Margin = -1.40% (FCF TTM -636.0m / Revenue TTM 45.43b)
Net Margin = 1.04% (Net Income TTM 472.0m / Revenue TTM 45.43b)
Gross Margin = 8.97% ((Revenue TTM 45.43b - Cost of Revenue TTM 41.35b) / Revenue TTM)
Gross Margin QoQ = 6.16% (prev 8.08%)
Tobins Q-Ratio = 0.45 (Enterprise Value 7.07b / Total Assets 15.56b)
Interest Expense / Debt = 1.32% (Interest Expense 52.0m / Debt 3.95b)
Taxrate = 19.86% (117.0m / 589.0m)
NOPAT = 625.9m (EBIT 781.0m * (1 - 19.86%))
Current Ratio = 1.69 (Total Current Assets 12.44b / Total Current Liabilities 7.37b)
Debt / Equity = 0.97 (Debt 3.95b / totalStockholderEquity, last quarter 4.07b)
Debt / EBITDA = -0.31 (Net Debt -298.0m / EBITDA 976.0m)
Debt / FCF = 0.47 (negative FCF - burning cash) (Net Debt -298.0m / FCF TTM -636.0m)
Total Stockholder Equity = 4.29b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.03% (Net Income 472.0m / Total Assets 15.56b)
RoE = 10.99% (Net Income TTM 472.0m / Total Stockholder Equity 4.29b)
RoCE = 9.69% (EBIT 781.0m / Capital Employed (Equity 4.29b + L.T.Debt 3.77b))
RoIC = 7.93% (NOPAT 625.9m / Invested Capital 7.89b)
WACC = 4.45% (E(7.37b)/V(11.32b) * Re(6.27%) + D(3.95b)/V(11.32b) * Rd(1.32%) * (1-Tc(0.20)))
Discount Rate = 6.27% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: -100.0 | Cagr: -6.58%
[DCF] Fair Price = unknown (Cash Flow -636.0m)
EPS Correlation: -44.08 | EPS CAGR: -52.38% | SUE: -4.0 | # QB: 0
Revenue Correlation: 97.69 | Revenue CAGR: 10.70% | SUE: 2.55 | # QB: 6
EPS next Quarter (2026-06-30): EPS=1.07 | Chg7d=+0.000 | Chg30d=+0.031 | Revisions Net=+0 | Analysts=6
EPS current Year (2026-12-31): EPS=5.54 | Chg7d=-0.000 | Chg30d=-1.416 | Revisions Net=-5 | Growth EPS=-49.8% | Growth Revenue=-2.1%
EPS next Year (2027-12-31): EPS=5.77 | Chg7d=+0.000 | Chg30d=-1.397 | Revisions Net=-2 | Growth EPS=+76.9% | Growth Revenue=+5.5%
[Analyst] Revisions Ratio: -1.00 (0 Up / 5 Down within 30d for Current Year)
[Growth] Implied Growth Rate = 1.6% (Discount Rate 7.9% - Earnings Yield 6.3%)
[Growth] Growth Spread = -5.3% (Analyst -3.7% - Implied 1.6%)
External Resources